Relapsed Non-Hodgkin Lymphoma Clinical Trial
Official title:
A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
This trial is to assess the safety & efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.
There is an emerging clinical data to confirm that Programmed death-1 (PD-1)blockade is safe
and viable in lymphoma.
The investigators hypothesize that the novel immune platform of pembrolizumab and
lenalidomide, will be safe and well tolerated in patients with Relapsed Refractory (RR)
Hodgkin Lymphoma (HL) and non-Hodgkin lymphoma (NHL) and that this combination will result in
a complete response (CR) rate of 50% in patients with RR HL.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05420493 -
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06049381 -
Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
|
||
| Recruiting |
NCT06104592 -
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
|
Phase 2 | |
| Recruiting |
NCT06158386 -
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05826535 -
Study of IMPT-314 in R/R Aggressive B-cell NHL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04012892 -
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05621096 -
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Recruiting |
NCT05828589 -
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Completed |
NCT02181478 -
Intra-Osseous Co-Transplant of UCB and hMSC
|
Early Phase 1 | |
| Not yet recruiting |
NCT06097455 -
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
|
Early Phase 1 | |
| Recruiting |
NCT05967416 -
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05691153 -
ThisCART19A for B-NHL Relapsed After Auto-CAR T
|
Phase 1 | |
| Not yet recruiting |
NCT05746858 -
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)
|